Patents Assigned to GlaxoSmithKline
  • Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the MAGE-A3-marker
    Patent number: 8936919
    Abstract: The present invention relates to MAGE-3 specific primers and probes for use new diagnostic kits and methods. The invention further relates to immunotherapeutic treatment of specific populations of cancer patients, suffering from MAGE-3 expressing tumors.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: January 20, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Gabriele Annemarie Beer, Thierry Coche, Olivier Gruselle, Dennis Salonga, Craig Lawrence Stephens
  • Conjugation process for PNAG and a carrier protein
    Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Modified tuberculosis antigens
    Patent number: 8932600
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: January 13, 2015
    Assignees: GlaxoSmithKline Biologicals S.A., Glaxo Group Limited
    Inventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
  • Vaccine
    Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • TRPV4 antagonists
    Patent number: 8927585
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Intellectual Property (NO.2) Limited
    Inventors: Carl Brooks, Mui Cheung, Krista B. Goodman, Marlys Hammond
  • Medical product dispensing systems and methods
    Patent number: 8930207
    Abstract: Methods and systems for transferring restricted distribution medical products to an over-the-counter general sales environment are provided. Methods and systems of dispensing non-prescription, behind-the-counter medical products from a vending machine in a general sales location are also provided. In some embodiments, methods and systems are provided for dispensing a medical product from a vending machine in a general sales location based, at least in part, on biometric data collected from the purchaser and, in some instances, based on self-selection and/or de-selection criteria, is provided. Further, methods and systems of switching prescription medical products to non-prescription, over-the-counter medical products are provided.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Daniel Paul Keravich, Richard Alexander McGregor, George Michael Quesnelle
  • NUCLEIC ACID MOLECULE
    Publication number: 20150004659
    Abstract: The disclosure relates to a nucleic acid molecule isolated from a Papaver somniferum cultivar that produces the opiate alkaloid noscapine which comprises 10 genes involved in the biosynthesis of opiate alkaloids.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 1, 2015
    Applicant: GlaxoSmithKline Australia Pty Limited
    Inventors: Thilo Winzer, Ian Alexander Graham, Tracy Carol Walker
  • CASB7439 constructs
    Patent number: 8916514
    Abstract: The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: December 23, 2014
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Normand Blais, Martine Harvey, Anthony Pilorget, Clement Rioux, Remi Palmantier
  • Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
    Patent number: 8912205
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: December 16, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Imidazopyridine derivatives as PI3 kinase
    Patent number: 8906910
    Abstract: This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective imidizopyridine compounds for treating cancer.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: December 9, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Ralph A. Rivero, Rosanna Tedesco
  • Combination for the treatment of cancer
    Patent number: 8906879
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 4-amino-1-(2-deoxy-2,2-difluoro-?-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on 2?, 2?-difluoro-2?-deoxycytidine, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Douglas J. DeMarini, Ngocdiep T. Le
  • NEW COMPOUNDS
    Publication number: 20140357594
    Abstract: This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—useful in the treatment of cancer and hyperproliferative diseases.
    Type: Application
    Filed: October 23, 2012
    Publication date: December 4, 2014
    Applicant: GlaxoSmithkline Intellectual Property (No.2) Limited
    Inventors: Thomas Francis Hendrickson, Koc-Kan Ho, Michael David Saunders, Brian John Stevens, Krzysztof Swierczek, Kevin Bret Wright
  • Peptide deformylase inhibitors
    Patent number: 8901119
    Abstract: The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 2, 2014
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Yuhong Fang, James Hoffman, Joseph M. Karpinski, Andrew Nicholson Knox, Xiangmin Liao, Donghui Qin, Dongchuan Shi, Jared T. Spletstoser
  • AZAINDAZOLES
    Publication number: 20140343056
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 20, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • Chemica compounds
    Patent number: 8889726
    Abstract: Disclosed are compounds of Formula I, Formula II, and Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Subramanian Baskaran, Richard Martin Grimes, Wieslaw Mieczyslaw Kazmierski, Martin Robert Leivers
  • Vaccine
    Patent number: 8889146
    Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Ventzislav B. Vassilev, Virginie Van Scherpenzeel Thim, Normand Blais, Patrick Rheault
  • Continuous coating of pellets
    Patent number: 8887659
    Abstract: A continuous dosage form coating apparatus uses vibrational impulses to maintain a dosage forms in a fluid state to expose them to a coating material atomized by spraying.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline LLC
    Inventor: Frederick H. Fiesser
  • PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES
    Publication number: 20140336175
    Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 13, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
  • Immunogenic composition
    Patent number: 8883163
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 11, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • THERAPEUTIC PEPTIDES
    Publication number: 20140329742
    Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 6, 2014
    Applicant: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Steven Thomas Dock, Andrew James Carpenter, Robert Neil Hunter, III, Yulin Wu, Ved P. Srivastava